Top Markets
#1 Islamic Coin Islamic Coin +154.45%
#2 PulseChain PulseChain +49.22%
#3 RedStone RedStone +23.10%
#4 MarsCoin MarsCoin +14.90%
#5 BOOK OF MEME BOOK OF MEME +14.69%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.37%
#7 Nockchain Nockchain +11.14%
#8 Starpower Starpower +9.36%
#9 Venom Venom +9.22%
#10 Lighter Lighter +9.20%
Coin of the day
Islamic Coin Islamic Coin
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Pozycja w akcjach #28047
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Cena akcji
$0.55
Ostatnia synchronizacja: 2025-02-11
Kapitalizacja rynkowa
$28.90M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Marinus Pharmaceuticals, Inc. (MRNS)

Kategoria

Healthcare
Wskaźnik P/S dla Marinus Pharmaceuticals, Inc. (MRNS)
Wskaźnik P/S na dzień August 2026 TTM: 0.98
Według najnowszych raportów finansowych i ceny akcji Marinus Pharmaceuticals, Inc., obecny wskaźnik P/S (TTM) wynosi 0.98. Na koniec 2022 wynosił 1.53.
Historia wskaźnika P/S dla Marinus Pharmaceuticals, Inc. od 2012 do 2026
Wskaźnik P/S na koniec każdego roku
Rok Wskaźnik P/S Zmień
2026 (TTM) 0.98 -79.24%
2023 4.72 209.16%
2022 1.53 -78.52%
2021 7.10 -85.33%
2020 48.41 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 -100.00%
2012 161.27 0.00%
Wskaźnik P/S dla podobnych firm lub konkurentów
Firma Wskaźnik P/S Różnica wskaźnika P/S Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 937.53%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 1,050.68%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 933.60%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 201.18%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH